Liquidia Corporation (LQDA) Research
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Market snapshot
- Symbol
- LQDA
- Price
- $71.07
- Day change
- +3.53%
- Market cap
- $6.3B
- P/E ratio
- 280.41x
- 52-week range
- 11.85-73.22
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
- Analyst price target
- $68.00
Recent news
- These Analysts Boost Their Forecasts On Liquidia After Upbeat Q1 Results
Liquidia Corp (NASDAQ:LQDA) on Monday reported better-than-expected first-quarter financial results.
- This Drug Stock Nears A Buy Point, With Profit Set To Explode
This drug stock is testing a moving average in a base. This biopharma name has a patented technology to administer its drug.
Peer companies
Recent insider activity
- JOHNSON DAVID EDWARD — A-Award (5882 shares) on 2026-06-16
- SINGH RAMAN — A-Award (5882 shares) on 2026-06-16
- Bloch Stephen M — A-Award (5882 shares) on 2026-06-16
- deGoa Damian — A-Award (5882 shares) on 2026-06-16
- Horobin Joanna — A-Award (5882 shares) on 2026-06-16
Open Liquidia Corporation (LQDA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.